Antiarrhythmic Therapy to Prevent Atrial Fibrillation after Cardiac Surgery
Cardiac surgery and the postoperative state are associated with increased catecholamine levels . Therefore, beta-blockers are logical agents to prevent atrial fibrillation in this setting. Indeed, many trials have shown a benefit with prophylactic beta-blockade [2-9]. However, the data regarding beta-blockers must be interpreted with caution. Some of the apparent benefit of beta-blockers may be explained by beta-blocker withdrawal in patients assigned to placebo. In addition, many of the beta-blocker trials excluded patients with left ventricular dysfunction and obstructive lung disease, and patients undergoing concomitant valvular surgery. Because of the limitations of beta-blockers and because there is a significant incidence of postoperative atrial fibrillation despite beta-blocker prophylaxis, other pharmacological approaches to prevent postoperative atrial fibrillation have been investigated.
KeywordsAtrial Fibrillation Coronary Artery Bypass Grafting Antiarrhythmic Drug Postoperative Atrial Fibrillation Supraventricular Tachyarrhythmia
Unable to display preview. Download preview PDF.
- 17.Laub GW, Janeira L, Muralidharan S, Riebman JB, Chen C, Neary M, Fernandez J, Adkins MS, McGrath LB. Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: A prospective, double-blind, randomized, placebo-controlled pilot study. Critic Care Med 1993;21:1474–8.CrossRefGoogle Scholar
- 18.Janssen J, Loomans L, Harink J, Taams M, Brunninkhuis L, van der Starre P, Kootstra G. Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: A randomized open trial. J Vasc Dis 1986;37:601–9.Google Scholar
- 19.Suttorp MJ, Kingma JH, Tjon Joe Gin RM, van Hemel NM, Koomen EM, Defauw JA, Adan AJM, Ernst SM. Efficacy and safety of low-and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovas Surg 1990;100:921–6.Google Scholar
- 25.Guarnieri T. Amiodarone Reduces CABG Hospitalization (ARCH) trial. Presented as a Late Breaking Clinical Trial at the 47th Annual Scientific Session of the American College of Cardiology. March 1998.Google Scholar
- 27.The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. European Heart Journal 1997;18:649–54.Google Scholar
- 30.Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man KC, Strickberger SA, Morady F. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997;5:1542–5019.Google Scholar
- 32.Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856–63.PubMedGoogle Scholar
- 37.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. 1SIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–85.CrossRefGoogle Scholar
- 39.Chun S, Sager P, Stevenson W, Nademanee K, Middlekauff H, Singh B. Amiodarone is highly effective in maintaining NSR in refractory atrial fibrillation/flutter. J Am Coll Cardiol 1993;21:203A.Google Scholar
- 43.Hondeghem LM. Class III agents: amiodarone, bretylium, and sotalol. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: WB. Saunders, 1995:1330–6.Google Scholar